Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;44(2):223-229.
doi: 10.3899/jrheum.160618. Epub 2016 Dec 1.

A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome

Rohit Aggarwal  1   2 , Namrata Dhillon  3   4 , Noreen Fertig  3   4 , Diane Koontz  3   4 , Zengbiao Qi  3   4 , Chester V Oddis  3   4
Affiliations

A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome

Rohit Aggarwal et al. J Rheumatol. 2017 Feb.

Abstract

Objective: To evaluate the utility of anticytoplasmic autoantibody (anti-CytAb) in antisynthetase antibody-positive (anti-SynAb+) patients.

Methods: Anti-SynAb+ patients were evaluated for antinuclear antibody (ANA) and anti-CytAb [cytoplasmic staining on indirect immunofluorescence (IIF)] positivity. Anti-SynAb+ patients included those possessing anti-Jo1 and other antisynthetase autoantibodies. Control groups included scleroderma, systemic lupus erythematosus, Sjögren syndrome, rheumatoid arthritis, and healthy subjects. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy of anti-CytAb, and ANA were assessed. Anti-CytAb and ANA testing was done by IIF on human epithelial cell line 2, both reported on each serum sample without knowledge of the clinical diagnosis or final anti-SynAb results.

Results: Anti-SynAb+ patients (n = 202; Jo1, n = 122; non-Jo1, n = 80) between 1985-2013 with available serum samples were assessed. Anti-CytAb showed high sensitivity (72%), specificity (89%), NPV (95%), and accuracy (86%), but only modest PPV (54%) for anti-SynAb positivity. In contrast, ANA showed only modest sensitivity (50%) and poor specificity (6%), PPV (9%), NPV (41%), and accuracy (12%). Positive anti-CytAb was significantly greater in the anti-SynAb+ patients than ANA positivity (72% vs 50%, p < 0.001), and 81/99 (82%) ANA-negative patients in the anti-SynAb+ cohort had positive anti-CytAb. In contrast, the control groups showed high rates for ANA positivity (93.5%), but very low rates for anti-CytAb positivity (11.5%). Combining anti-CytAb or Jo1 positivity showed high sensitivity (92%) and specificity (89%) for identification of anti-SynAb+ patients.

Conclusion: Assessing patients for anti-CytAb serves as an excellent screen for anti-SynAb+ patients using simple IIF. Cytoplasmic staining should be assessed and reported for patients suspected of having antisynthetase syndrome and a negative ANA should not be used to exclude this diagnosis.

Keywords: ANTINUCLEAR ANTIBODY; ANTISYNTHETASE AUTOANTIBODY; ANTISYNTHETASE SYNDROME; CYTOPLASMIC ANTIBODY STAINING; DERMATOMYOSITIS; POLYMYOSITIS.

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

  • [Antisynthetase syndromes].
    Bauhammer J, Fiehn C. Bauhammer J, et al. Z Rheumatol. 2019 Sep;78(7):645-655. doi: 10.1007/s00393-019-0665-0. Z Rheumatol. 2019. PMID: 31346706 Review. German.
  • Prevalence of Anti-Synthetase Syndrome in Patients of Interstitial Lung Disease with Connective Tissue Diseases and Autoimmune Features: A Cross-Sectional Study.
    Mb I, Deepak D, Bhatta A, Lalwani G, Sharma B, Somayya V, Chhabra M, Duggal N. Mb I, et al. Mediterr J Rheumatol. 2025 Mar 31;36(1):107-115. doi: 10.31138/mjr.180324.dtc. eCollection 2025 Mar. Mediterr J Rheumatol. 2025. PMID: 40557171 Free PMC article.
  • Anti-NT5c1A Autoantibodies as Biomarkers in Inclusion Body Myositis.
    Amlani A, Choi MY, Tarnopolsky M, Brady L, Clarke AE, Garcia-De La Torre I, Mahler M, Schmeling H, Barber CE, Jung M, Fritzler MJ. Amlani A, et al. Front Immunol. 2019 Apr 9;10:745. doi: 10.3389/fimmu.2019.00745. eCollection 2019. Front Immunol. 2019. PMID: 31024569 Free PMC article.
  • Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies.
    Hamaguchi Y, Kuwana M, Takehara K. Hamaguchi Y, et al. Clin Rheumatol. 2020 Nov;39(11):3489-3497. doi: 10.1007/s10067-020-04973-0. Epub 2020 May 8. Clin Rheumatol. 2020. PMID: 32385758
  • Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course.
    Cavagna L, Trallero-Araguás E, Meloni F, Cavazzana I, Rojas-Serrano J, Feist E, Zanframundo G, Morandi V, Meyer A, Pereira da Silva JA, Matos Costa CJ, Molberg O, Andersson H, Codullo V, Mosca M, Barsotti S, Neri R, Scirè C, Govoni M, Furini F, Lopez-Longo FJ, Martinez-Barrio J, Schneider U, Lorenz HM, Doria A, Ghirardello A, Ortego-Centeno N, Confalonieri M, Tomietto P, Pipitone N, Rodriguez Cambron AB, Blázquez Cañamero MÁ, Voll RE, Wendel S, Scarpato S, Maurier F, Limonta M, Colombelli P, Giannini M, Geny B, Arrigoni E, Bravi E, Migliorini P, Mathieu A, Piga M, Drott U, Delbrueck C, Bauhammer J, Cagnotto G, Vancheri C, Sambataro G, De Langhe E, Sainaghi PP, Monti C, Gigli Berzolari F, Romano M, Bonella F, Specker C, Schwarting A, Villa Blanco I, Selmi C, Ceribelli A, Nuno L, Mera-Varela A, Perez Gomez N, Fusaro E, Parisi S, Sinigaglia L, Del Papa N, Benucci M, Cimmino MA, Riccieri V, Conti F, Sebastiani GD, Iuliano A, Emmi G, Cammelli D, Sebastiani M, Manfredi A, Bachiller-Corral J, Sifuentes Giraldo WA, Paolazzi G, Saketkoo LA, Giorgi R, Salaffi F, Cifrian J, Caporali R, Locatelli F, Marchioni E, Pesci A, Dei G, Pozzi MR, Claudia L, Distler J, Knitza J, Schett G, Iannone F, Fo… See abstract for full author list ➔ Cavagna L, et al. J Clin Med. 2019 Nov 18;8(11):2013. doi: 10.3390/jcm8112013. J Clin Med. 2019. PMID: 31752231 Free PMC article.
See all "Cited by" articles

Substances

Supplementary concepts

LinkOut - more resources